{"id":13253,"date":"2013-06-24T16:28:15","date_gmt":"2013-06-24T16:28:15","guid":{"rendered":"http:\/\/www.alfredoferrer.com\/?p=13253"},"modified":"2024-12-03T20:44:55","modified_gmt":"2024-12-03T20:44:55","slug":"jetrea-first-and-only-treatment-for-vitreomacular-traction-and-macular-hole-shortly-available","status":"publish","type":"post","link":"https:\/\/alfredoferrer.com\/en\/jetrea-first-and-only-treatment-for-vitreomacular-traction-and-macular-hole-shortly-available\/","title":{"rendered":"Jetrea\u00ae, First and Only Treatment for Vitreomacular Traction and Macular Hole, Shortly Available."},"content":{"rendered":"<p>Basel \u2014 March 18, 2013<\/p>\n<p><strong>Alcon<\/strong>, the global leader in eye care and a division of <strong>Novartis<\/strong>, announces that the European Commission has approved Jetrea\u00ae<strong> intravitreal injection<\/strong> (ocriplasmin) in the EU for the treatment of <strong>vitreomacular traction (VMT)<\/strong>, including when associated with <strong>macular hole<\/strong> of diameter less than or equal to 400 microns. VMT is often responsible for progressive sight-threatening symptoms and irreversible vision loss, and is estimated to affect between 250,000 to 300,000 people in Europe alone.<\/p>\n<p>The pivotal studies, published in the New England Journal of Medicine, showed that patients who were treated with<strong> Jetrea successfully achieved resolution<\/strong> of VMT and closure of macular holes as compared to placebo at day 28.<\/p>\n<p><strong>This treatment will avoid surgery in many cases and will be available in our centre shortly.<\/strong><\/p>\n<p>More info: <a href=\"http:\/\/www.novartis.com\/newsroom\/media-releases\/en\/2013\/1685825.shtml\" target=\"_blank\" rel=\"noopener\">http:\/\/www.novartis.com\/newsroom\/media-releases\/en\/2013\/1685825.shtml<\/a><\/p>\n<p>Source: <a href=\"http:\/\/www.novartis.com\" target=\"_blank\" rel=\"noopener\">www.novartis.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Basel \u2014 March 18, 2013 Alcon, the global leader in eye care and a division of Novartis, announces that the European Commission has approved Jetrea\u00ae intravitreal injection (ocriplasmin) in the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":314,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[37],"tags":[],"aioseo_notices":[],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/alfredoferrer.com\/en\/wp-json\/wp\/v2\/posts\/13253"}],"collection":[{"href":"https:\/\/alfredoferrer.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alfredoferrer.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alfredoferrer.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/alfredoferrer.com\/en\/wp-json\/wp\/v2\/comments?post=13253"}],"version-history":[{"count":1,"href":"https:\/\/alfredoferrer.com\/en\/wp-json\/wp\/v2\/posts\/13253\/revisions"}],"predecessor-version":[{"id":18352,"href":"https:\/\/alfredoferrer.com\/en\/wp-json\/wp\/v2\/posts\/13253\/revisions\/18352"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alfredoferrer.com\/en\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/alfredoferrer.com\/en\/wp-json\/wp\/v2\/media?parent=13253"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alfredoferrer.com\/en\/wp-json\/wp\/v2\/categories?post=13253"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alfredoferrer.com\/en\/wp-json\/wp\/v2\/tags?post=13253"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}